These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17226044)

  • 1. Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling.
    Hanifi-Moghaddam P; Boers-Sijmons B; Klaassens AH; van Wijk FH; den Bakker MA; Ott MC; Shipley GL; Verheul HA; Kloosterboer HJ; Burger CW; Blok LJ
    J Mol Med (Berl); 2007 May; 85(5):471-80. PubMed ID: 17226044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen.
    Klaassens AH; van Wijk FH; Hanifi-Moghaddam P; Sijmons B; Ewing PC; Ten Kate-Booij MJ; Kooi GS; Kloosterboer HJ; Blok LJ; Burger CW
    Fertil Steril; 2006 Aug; 86(2):352-61. PubMed ID: 16828477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen-and progesterone-responsive endometrial cancer cell line.
    Hanifi-Moghaddam P; Sijmons B; Ott MC; van Ijcken WF; Nowzari D; Kuhne EC; van der Spek P; Kloosterboer HJ; Burger CW; Blok LJ
    J Mol Endocrinol; 2006 Dec; 37(3):405-13. PubMed ID: 17170081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difference in signalling between various hormone therapies in endometrium, myometrium and upper part of the vagina.
    Hanifi-Moghaddam P; Boers-Sijmons B; Klaassens AH; van Wijk FH; Van Ijcken WF; Van der Spek P; Verheul HA; Kloosterboer HJ; Burger CW; Blok LJ
    Hum Reprod; 2008 Feb; 23(2):298-305. PubMed ID: 18077316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
    Langer RD; Landgren BM; Rymer J; Helmond FA;
    Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate.
    Verheul HA; Blok LJ; Burger CW; Hanifi-Moghaddam P; Kloosterboer HJ
    Reprod Sci; 2007 Feb; 14(2):160-8. PubMed ID: 17636227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial effects of tibolone.
    Archer DF; Hendrix S; Gallagher JC; Rymer J; Skouby S; Ferenczy A; den Hollander W; Stathopoulos V; Helmond FA
    J Clin Endocrinol Metab; 2007 Mar; 92(3):911-8. PubMed ID: 17192288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-alpha mRNA in Ishikawa cells. Implication for tibolone's effects on the endometrium.
    Mirkin S; Archer DF
    Maturitas; 2007 Aug; 57(4):338-46. PubMed ID: 17478063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
    Odmark IS; Carlström K; Jonsson B; Jonasson AF
    Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
    Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone.
    Hanifi-Moghaddam P; Gielen SC; Kloosterboer HJ; De Gooyer ME; Sijbers AM; van Gool AJ; Smid M; Moorhouse M; van Wijk FH; Burger CW; Blok LJ
    J Clin Endocrinol Metab; 2005 Feb; 90(2):973-83. PubMed ID: 15572424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tibolone and its metabolites on prolactin and insulin-like growth factor binding protein-1 expression in human endometrial stromal cells.
    Guzel E; Buchwalder L; Basar M; Kayisli U; Ocak N; Bozkurt I; Lockwood CJ; Schatz F
    Gynecol Endocrinol; 2015 May; 31(5):414-8. PubMed ID: 25856298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
    Ziaei S; Moghasemi M; Faghihzadeh S
    Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy.
    Meuwissen JH; Wiegerinck MA; Haverkorn MJ
    Maturitas; 1995 Feb; 21(2):121-5. PubMed ID: 7752949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.